The research collaboration, under which Septerna will receive more than $200 million in upfront and near-term fees, is the ...

New research reveals that semaglutide significantly improves liver health in MASH patients. A new study published in the New ...

Frier Levitt will host a May 15 webinar on legal risks, compounding regulations and market trends impacting GLP-1 prescribers ...

New research published in the American Journal of Health-System Pharmacy suggests a possible link between the GLP-1 drug ...

New animal research being presented at this year's European Congress on Obesity (ECO) in Malaga, Spain (11-14 May), reveals ...

Limited effectiveness, weight regain, and high prevalence of adverse events are the three key limitations of ...

The FDA has accepted for review the New Drug Application for a 25mg oral formulation of semaglutide for chronic weight management.

The new acquisition from Boston Pharmaceuticals adds to a wave of dealmaking undertaken by GSK to build its liver disease ...

In SELECT, semaglutide was associated with a 41% reduction in major CV events within 6 months — ie, before weight loss or ...

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes ...

With the active ingredients in drugs like Ozempic and Zepbound no longer in shortage, access to medicine for millions who had ...

Scientists herald 150 new jabs and pills to tackle obesity going through the research pipeline - but issue urgent warning to ...